UBS raised the firm’s price target on Guardant Health (GH) to $80 from $70 and keeps a Buy rating on the shares following the investor day. The company upped its 2028 sales targets and advanced its cash flow breakeven 12 months earlier, the analyst tells investors in a research note. UBS increased its sales forecasts to reflect more durable volume growth in Guardant’s oncology business and better selling prices.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health’s Strategic Advancements and Growth Potential Earns Buy Rating
- Guardant Health Hosts Investor Day in NYC
- Guardant Health, Quest Diagnostics announce blood-based screening test pact
- Guardant Health: Buy Rating Backed by Growth Potential and Innovation in Cancer Screening
- Craig-Hallum healthcare/pharma analysts hold analyst/industry conference call